09.09.19

Gemini version available ♊︎

The European Patent Convention (“EPC”) Does Not Allow Patenting of Life Itself

Posted in Europe, Patents at 10:10 pm by Dr. Roy Schestowitz

Wedding Invitation

Summary: Unless the underlying rules are respected and Europe’s largest patent office actually follows the laws it’s governed by, Europe’s patent system won’t promote innovation; the European Patent Office’s decision on Alexion (patent application 3124029 rejected) is good news

BOTH the European Patent Office (EPO) and the U.S. Patent and Trademark Office (USPTO) still grapple with a question that should not even be asked. Why? Because the answer to it should be obvious. The American 35 U.S.C. § 101 is pretty clear about naturally-recurring phenomena and Europe has already spoken — many times in fact — about patents on life. If only Campinos and Battistelli actually obeyed the law…

Today’s EPO not only tolerates patents on life and nature; it’s also actively promoting software patents in Europe. The EPO is totally out of control!

To our surprise, and for a change, yesterday we saw this article from Phil Taylor (pharmaphorum). When patents are misused not for elevation of the sciences but for monopoly that enables ruinous price hikes in medicines this is what should happen:

The European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster drug Soliris, setting up biosimilar competition from 2022.

The EPO delivered its verdict late last week but Alexion’s share price remained unscathed by the news, suggesting investors are confident that the company will be able to migrate revenues to its follow-up drug Ultomiris by that date.

In a brief Securities & Exchange Commission filing, Alexion said the EPO had rejected its attempt to extend two patents for Soliris (eculizumab) and it is considering an appeal.

It’s also facing a patent challenge to Soliris in the US from Amgen, which is developing a biosimilar version of the drug called ABP 959 and has petitioned the US Patent and Trademark Office (USPTO) to review Alexion’s intellectual property on the drug. It made the move after Alexion won an extension on its US patent life until 2027.

Soliris – a complement C5 inhibitor used to treat several rare diseases including paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS) – achieved sales of $1.94 billion in the first six months of the year, accounting for more than 80% of the biotech’s total sales in that period.

Kelly Davio (Center for Biosimilars, i.e. patent maximalists and monopolists) responded as follows to the EPO denying antibody patents:

Last week, Alexion disclosed in a filing to the US Securities and Exchange Commission that the European Patent Office (EPO) did not grant Alexion its request for 2 patents on its brand-name eculizumab product, Soliris, a C5 complement inhibitor that treats rare and ultrarare diseases.

The Form 8-K, dated September 5, indicates that the office declined to grant patent application 3124029, which covers a pharmaceutical composition comprising an antibody or antibody fragment binding to C5 for use in treating a patient with paroxysmal nocturnal hemoglobinuria (PNH), and patent application 3167888, which relates to the composition of matter of eculizumab.

This will probably be mentioned by patent maximalists’ blogs such as IP Kat and Kluwer Patent Blog in days to come. Both like to promote patents on life/nature, especially in their current composition (they’re both run by Big Pharma firms and their lawyers).

Mind this new IP Kat comment from “CRISPR scientist” (profiteer), who defends monopolies on life itself, ignoring health risks: “It would be feasible, but it would require a separate round of gene editing since no one could want to introduce a marker into the functional gene that is the subject of the first round of gene editing. The gene editing process is complicated, time consuming and costly. And every round of editing harbors the risk of additional unwanted modifications. So, can there really be a benefit if one has to perform an additional round of gene editing only for administrative sake? I shall think no. [] I don’t think that reasonable people are actually worried about their own health. Genetic material in the food you consume has very little possibility to influence your body. And I do doubt that it may cause food allergies. As the article correctly points out, the actual risk is what will happen to the ecosystem. I agree that heavy dependence on fertilizer or herbicides is detrimental. However, that is not what CRISPR is about. Gene editing is simply a stunning, secure and reliable technique to modify a plant’s genome. Banning gene editing because it may cause harm in certain scenarios is much like banning operations per se simply because people may die if operated wrongly. We can’t igonore the benefits that gene editing is bringing a world where we need more nurtrious food and crops that are able to resist climate change.”

This is the classic propaganda/talking point from GMO proponents. We spent a lot of time and energy confronting these lies about a decade ago when we wrote a great deal about Monsanto, now part of Bayer in Germany.

Anyway, it’s nice to see the EPO rejecting bad patents, probably showing a little bit of respect for the EPC, for a change…

Miquel Montañá has just mentioned the EPC in relation to a case outside the EPO’s remit; he ought to take note of the fact that the EPO’s management violates the EPC every day, rendering it moot! To quote yesterday’s post from Montañá:

As readers are well aware, one of the difficult tasks when applying article 69 of the European Patent Convention (“EPC”) and its Protocol of Interpretation is to strike the right balance between “interpreting” the claims in the context of the specification, while, at the same time, avoiding “importing” features of the specification into the claims. A judgment of 12 February 2019 from the Barcelona Court of Appeal recently published has warned against the risk of using specification for the purpose of unduly restricting the scope of protection of the claims.

[...]

Interestingly, the Court of Appeal relied on the case law from the European Patent Office (“EPO”) Boards of Appeal (for example, T 1018/02, T 1395/07, T-544/89 and T-681/01) noting that, although they do not decide infringement cases, they do have to interpret the scope of protection of the claims when they examine validity.

Finally, the Court of Appeal added that, although in the past the Court had “read” in the claims features mentioned in the specification which were not explicitly mentioned in the claims, this was done in exceptional cases only, when the feature omitted in the claim was essential for the functioning of the invention. The Court of Appeal added that “But this is not the case, because the interpretation of the defendant and its expert relies solely and exclusively on the preferred embodiments disclosed in the drawings.”

All in all, the main teaching of this interesting judgment is that when applying article 69 of the EPC and its Protocol of Interpretation, care must be applied to avoid “importing” features of the specification into the claims.

Readers are well aware, as we’ve shown many examples lately, that European courts very often deviate from EPO judgments, which sometimes get delivered by the Boards that are afraid of the Office. This lack of independence is, in its own right, a gross violation of the EPC.

Share in other sites/networks: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Reddit
  • email

Decor ᶃ Gemini Space

Below is a Web proxy. We recommend getting a Gemini client/browser.

Black/white/grey bullet button This post is also available in Gemini over at this address (requires a Gemini client/browser to open).

Decor ✐ Cross-references

Black/white/grey bullet button Pages that cross-reference this one, if any exist, are listed below or will be listed below over time.

Decor ▢ Respond and Discuss

Black/white/grey bullet button If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

DecorWhat Else is New


  1. IRC Proceedings: Tuesday, June 06, 2023

    IRC logs for Tuesday, June 06, 2023



  2. NOW LIVE: Working for the Public — Universities, Software and Freedom - a Talk by Richard Stallman at Università di Pisa (Italy)

    As noted a few hours ago, Richard Stallman is delivering a talk at Università di Pisa this morning



  3. Richard Stallman's Talk is in Two Hours and There's a BigBlueButton Livestream

    Dr. Stallman is in Italy to give talks at universities this week; he will soon give a live talk, accessible in his site or directly at the source



  4. Links 06/06/2023: Angie 1.2.0, New EasyOS and EndeavourOS Released

    Links for the day



  5. Gemini Links 06/06/2023: OpenKuBSD, GrapheneOS, and More

    Links for the day



  6. Links 06/06/2023: OpenSUSE Plans for Leap

    Links for the day



  7. Gemini Links 06/06/2023: Bubble 4.0, Neutral News, and Older Bits

    Links for the day



  8. IBM's War on Open (Look at the Pattern of Layoffs at Red Hat)

    By abandoning OpenSource.com and OpenOffice.org/LibreOffice IBM sends out a clear signal that it doesn’t understand or simply does not care about the community of Free software users; its siege against the FSF and other institutions never ended and today we look at who’s being laid off or shown the door (the work environment is intentionally being made worse)



  9. Links 06/06/2023: IceWM 3.4.0 and Liveslak 1.7.0

    Links for the day



  10. Gemini Links 06/06/2023: Apple Might Kill VR, Tea Tea Deluxe 1.2.7 and Tea Land

    Links for the day



  11. IRC Proceedings: Monday, June 05, 2023

    IRC logs for Monday, June 05, 2023



  12. Links 05/06/2023: Debian 12 Almost Ready, Hong Kong 'Cannot' Remember Tiananmen Massacre

    Links for the day



  13. Gemini Links 05/06/2023: New Ship in Cosmic Voyage, Stack Overflow Moderator Strike

    Links for the day



  14. IRC Proceedings: Sunday, June 04, 2023

    IRC logs for Sunday, June 04, 2023



  15. Links 04/06/2023: Unifont 15.0.05 and PCLinuxOS Stuff

    Links for the day



  16. Gemini Links 04/06/2023: Wayland and the Old Computer Challenge

    Links for the day



  17. StatCounter: GNU/Linux (Including ChromeOS) Grows to 8% Market Share Worldwide

    This month’s numbers from StatCounter are good for GNU/Linux (including ChromeOS, which technically has both GNU and Linux); the firm assesses logs from 3 million sites and shows Windows down to 66% in desktops/laptops (a decade ago it was above 90%) with modest growth for GNU/Linux, which is at an all-time high, even if one does not count ChromeOS that isn’t freedom- or privacy-respecting



  18. Journalism Cannot and Quite Likely Won't Survive on the World Wide Web

    We’re reaching the point where the overwhelming majority of new pages on the Web (the World Wide Web) are basically junk, sometimes crafted not by humans; how to cope with this rapid deterioration is still an unknown — an enigma that demands hard answers or technical workarounds



  19. Do Not Assume Pensions Are Safe, Especially When Managed by Mr. EPOTIF Benoît Battistelli and António Campinos

    With the "hoax" that is the financial assessment by António Campinos (who is deliriously celebrating the inauguration of illegal and unconstitutional kangaroo courts) we urge EPO workers to check carefully the integrity of their pensions, seeing that pension promises have been broken for years already



  20. Links 04/06/2023: Why Flatpak and Wealth of Devices With GNU/Linux

    Links for the day



  21. Gemini Links 04/06/2023: Rosy Crow 1.1.3 and NearlyFreeSpeech.NET

    Links for the day



  22. IRC Proceedings: Saturday, June 03, 2023

    IRC logs for Saturday, June 03, 2023



  23. Links 04/06/2023: Azure Outage Again (So Many!) and Tiananmen Massacre Censored

    Links for the day



  24. Links 03/06/2023: Qubes OS 4.2.0 RC1 and elementaryOS Updates for May

    Links for the day



  25. Gemini Links 03/06/2023: Hidden Communities and Exam Prep is Not Education

    Links for the day



  26. Links 03/06/2023: IBM Betraying LibreOffice Some More (After Laying off LibreOffice Developers)

    Links for the day



  27. Gemini Links 03/06/2023: Bubble Woes and Zond Updates

    Links for the day



  28. Links 03/06/2023: Apache NetBeans 18 and ArcaOS 5.0.8

    Links for the day



  29. IRC Proceedings: Friday, June 02, 2023

    IRC logs for Friday, June 02, 2023



  30. The Developing World Abandons Microsoft Windows, GNU/Linux at All-Time Highs on Desktops/Laptops

    Microsoft, with 80 billion dollars in longterm debt and endless layoffs, is losing the monopolies; the media doesn’t mention this, but some publicly-accessible data helps demonstrate that


RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

Recent Posts